Sheffels P - Search Results

1

Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity.

Kharasch ED, Walker A, Hoffer C, Sheffels P. Kharasch ED, et al. Among authors: sheffels p. J Clin Pharmacol. 2005 Oct;45(10):1187-97. doi: 10.1177/0091270005280077. J Clin Pharmacol. 2005. PMID: 16172184 Clinical Trial.

2

Disposition of nasal, intravenous, and oral methadone in healthy volunteers.

Dale O, Hoffer C, Sheffels P, Kharasch ED. Dale O, et al. Among authors: sheffels p. Clin Pharmacol Ther. 2002 Nov;72(5):536-45. doi: 10.1067/mcp.2002.128386. Clin Pharmacol Ther. 2002. PMID: 12426517 Clinical Trial.

3

Disposition and miotic effects of oral alfentanil: a potential noninvasive probe for first-pass cytochrome P4503A activity.

Kharasch ED, Hoffer C, Walker A, Sheffels P. Kharasch ED, et al. Among authors: sheffels p. Clin Pharmacol Ther. 2003 Mar;73(3):199-208. doi: 10.1067/mcp.2003.30. Clin Pharmacol Ther. 2003. PMID: 12621385

4

Bioavailabilities of rectal and oral methadone in healthy subjects.

Dale O, Sheffels P, Kharasch ED. Dale O, et al. Among authors: sheffels p. Br J Clin Pharmacol. 2004 Aug;58(2):156-62. doi: 10.1111/j.1365-2125.2004.02116.x. Br J Clin Pharmacol. 2004. PMID: 15255797 Free PMC article. Clinical Trial.

5

Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone.

Kharasch ED, Hoffer C, Whittington D, Sheffels P. Kharasch ED, et al. Among authors: sheffels p. Clin Pharmacol Ther. 2004 Sep;76(3):250-69. doi: 10.1016/j.clpt.2004.05.003. Clin Pharmacol Ther. 2004. PMID: 15371986 Clinical Trial.

6

Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis.

Kharasch ED, Walker A, Hoffer C, Sheffels P. Kharasch ED, et al. Among authors: sheffels p. Clin Pharmacol Ther. 2004 Nov;76(5):452-66. doi: 10.1016/j.clpt.2004.07.006. Clin Pharmacol Ther. 2004. PMID: 15536460 Clinical Trial.

7

Metabolism of alfentanil by cytochrome p4503a (cyp3a) enzymes.

Klees TM, Sheffels P, Dale O, Kharasch ED. Klees TM, et al. Among authors: sheffels p. Drug Metab Dispos. 2005 Mar;33(3):303-11. doi: 10.1124/dmd.104.002709. Epub 2004 Nov 22. Drug Metab Dispos. 2005. PMID: 15557344

8

Evaluation of first-pass cytochrome P4503A (CYP3A) and P-glycoprotein activities using alfentanil and fexofenadine in combination.

Kharasch ED, Walker A, Hoffer C, Sheffels P. Kharasch ED, et al. Among authors: sheffels p. J Clin Pharmacol. 2005 Jan;45(1):79-88. doi: 10.1177/0091270004269705. J Clin Pharmacol. 2005. PMID: 15601808 Clinical Trial.

9

Enantiomeric metabolic interactions and stereoselective human methadone metabolism.

Totah RA, Allen KE, Sheffels P, Whittington D, Kharasch ED. Totah RA, et al. Among authors: sheffels p. J Pharmacol Exp Ther. 2007 Apr;321(1):389-99. doi: 10.1124/jpet.106.117580. Epub 2007 Jan 26. J Pharmacol Exp Ther. 2007. PMID: 17259447 Free article.

10

Pharmacogenetic determinants of human liver microsomal alfentanil metabolism and the role of cytochrome P450 3A5.

Klees TM, Sheffels P, Thummel KE, Kharasch ED. Klees TM, et al. Among authors: sheffels p. Anesthesiology. 2005 Mar;102(3):550-6. doi: 10.1097/00000542-200503000-00012. Anesthesiology. 2005. PMID: 15731592

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

24 results

Search Page

Filters